Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 2Completed 2Active not recruiting 2Terminated 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid, Acute 1Dendritic Cell Sarcoma, Interdigitating 1Acromesomelic dysplasia, Maroteaux type 1

Interventions

Specimen Handling 12Magnetic Resonance Spectroscopy 11Cyclophosphamide 10Biological Therapy 9Drug Therapy 8Dexamethasone 7Biopsy 7antineoplaston A10 6Nivolumab 6Complementary Therapies 6fludarabine 5antineoplaston AS 2-1 5aldesleukin 5Ipilimumab 5Etoposide 5Doxorubicin 5Cisplatin 5atezolizumab 4Vincristine 4Surgical Procedures, Operative 4Rituximab 4Paclitaxel 4Chemotherapy, Adjuvant 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4venetoclax 3olaparib 3dexamethasone acetate 3dexamethasone 21-phosphate 3copanlisib 3auricularum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × NIH × pevonedistat × Clear all
NCT03745352 2023-06-27

Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01415765 2019-12-17

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
LymphoidSarcoma

Acromesomelic dysplasia, Maroteaux type, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡